Shantha Bio, PATH to Develop Rotavirus Vaccine (India)
This article was originally published in PharmAsia News
Executive Summary
Shantha Biotechnics in India is developing a multivalent vaccine against rotavirus as part of a partnership with PATH, the global nonprofit health organization, and the National Institutes of Health. The parties are pursuing the accelerated development of a new vaccine that is safe, effective, and affordable. Licensed vaccines for rotavirus include Merck's RotaTeq and GSK's Rotatrix, but they are not available in the country at present. Shantha will be using technology licensed from the United States. The completion of preclinical toxicology studies will be followed by clinical trials in 2008. (Click here for more
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.